ASCO 2023

Formations et évènements

ASCO 2023

02-06 juin 2023

Chicago

5 abstracts IFCT à l'ASCO 2023

Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.
Filippo Gustavo Dall'Olio
Rapid Abstract Session
2 juin - E450 - 17:09

IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.

Quincy S. Chu

Oral abstract session

3 juin - Hall B1 - 16:48

Press release

Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.

Anne-Claire Toffart

Poster session

4 juin - Hall A - 08:00

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.

Lionel Falchero

Poster session
4 juin - Hall A - 08:00

IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).
Nicolas Girard
Poster session
4 juin - Hall A - 08:00

Retour au calendrier des évènements

En savoir +

Voir le site du congrès